Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01439815 · ClinicalTrials.gov registry record · Phase 4
An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo
A Phase 4 study, sponsored by ORA.
- Completed
- Registry status
- Phase 4
- Development phase
- 22
- Enrollment target
NCT01439815 is a Phase 4 study that has completed, run by ORA. The registered enrollment target is 22 participants.
The verdict
NCT01439815, a Phase 4 study, has completed, sponsored by ORA.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the onset of action of fluticasone propionate nasal spray compared to placebo nasal spray in reducing nasal allergic signs and symptoms following ragweed exposure in the Allergen BioCube (ABC) after up to 14 days of at home dosing.
Interventions
- DRUG Fluticasone Propionate Nasal Spray
- DRUG Saline Nasal Spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2011-09 |
| Est. Completion | 2011-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01439815
The ClinicalTrials.gov registry entry for NCT01439815 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ORA, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fluticasone Propionate Nasal Spray is the first listed.
NCT01439815 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01439815 about?
NCT01439815 is a clinical study titled "An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo". The purpose of this study is to evaluate the onset of action of fluticasone propionate nasal spray compared to placebo nasal spray in reducing nasal allergic signs and symptoms following ragweed exposure in the Allergen BioCube (ABC) after up to 14 days of at home dosing.
What is the current status of trial NCT01439815?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2011-09. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01439815?
The interventions under investigation include: Fluticasone Propionate Nasal Spray (DRUG), Saline Nasal Spray (DRUG).
Who is sponsoring clinical trial NCT01439815?
This trial is sponsored by ORA, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.